Wyss Institute at Harvard University Partners with Northpond Labs to Launch RNA Solutions Company EnPlusOne Biosciences; Startup Aims to Bring Versatile, Sustainable, and Scalable RNA Synthesis Technology to Market to Unlock Development of New RNA Drugs, Vaccines, and Gene-Editing Therapies

George Church, PhD, Co-Founder of EnPlusOne Biosciences
On December 19, 2022, the Wyss Institute for Biologically Inspired Engineering at Harvard University and EnPlusOne Biosciences (EnPlusOne Bio) announced that the startup company has signed a worldwide, exclusive licensing agreement with Harvard’s Office of Technology Development (OTD) that grants EnPlusOne Bio the rights to commercialize a novel, controlled enzymatic RNA oligonucleotide synthesis technology. The “ezRNA” platform technology was invented and advanced by Wyss Core Faculty member George Church, PhD, and an expert team of biologists, chemists, and life science entrepreneurs at the Wyss Institute, and supported and funded by Northpond Labs, the research and development-focused affiliate of Northpond Ventures, as the inaugural project of the Wyss Institute-Northpond Labs alliance. “My own early work on highly modified RNAs going back to 1973, and in vivo and in vitro chemistry for nucleic acid synthesis and modifications that I later developed with my lab finds a new and clinically highly relevant continuation in EnPlusOne’s approach, which could revolutionize the creation of future RNA therapeutics,” said Dr. Church, who co-founded EnPlusOne.
Login Or Register To Read Full Story